<DOC>
	<DOCNO>NCT00053027</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy cladribine work different way stop cancer cell divide stop grow die . Combining rituximab cladribine may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together cladribine work treat patient newly-diagnosed mantle cell lymphoma .</brief_summary>
	<brief_title>Rituximab Cladribine Treating Patients With Newly Diagnosed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether rituximab cladribine increase complete remission rate unconfirmed complete remission rate patient mantle cell lymphoma . - Determine time progression patient treat regimen . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . An initial cohort 6 patient Mayo Clinic receive rituximab IV 4-8 hour day 1 cladribine IV 2 hour day 4-8 . If 2 patient experience unacceptable toxicity first course , study discontinue ; otherwise , study open enrollment NCCTG site . ( The phase II study open enrollment 5/14/04 . ) Treatment repeat every 28 day total 2-6 course absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year , every 4 month 1 year , every 6 month 1 year , annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma* Measurable assessable disease define least one following : Lymph node tumor mass 2.0 cm least one dimension CT scan , MRI , plain radiograph imaging OR great 1.5 cm least one dimension physical exam Splenic enlargement , spleen palpable , least 3 cm leave costal margin Diffuse infiltration organ stomach , bone marrow , peripheral blood , liver , lung , bowel lymphoma without discrete mass would constitute assessable , measurable , disease No known CNS involvement NOTE : *If tumor tissue unavailable biopsy , blood bone marrow specimen may use establish patient eligibility provide fusion signal indicate presence ( 11 ; 14 ) ( q13 ; q32 ) fluorescence situ hybridization use CCND1/IGH AND mantle cell lymphoma involvement determine morphology PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Total direct bilirubin great upper limit normal ( ULN ) ( without secondary liver involvement ) SGOT great 3 time ULN ( 5 time ULN liver involvement ) Renal Creatinine great 2.0 mg/dL Cardiovascular No myocardial infarction within past 6 month No uncontrolled high blood pressure No unstable angina No serious uncontrolled cardiac arrhythmia No active congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day study participation HIV negative No malignancy within past 5 year except carcinoma situ cervix , resect basal cell squamous cell skin cancer , prostate cancer remission radical retropubic prostatectomy radiotherapy No medical psychiatric condition make patient poor risk study No active uncontrolled infection No known hypersensitivity rituximab component murine protein PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy mantle cell lymphoma Chemotherapy No prior chemotherapy mantle cell lymphoma Endocrine therapy No prior endocrine therapy mantle cell lymphoma Radiotherapy No prior radiotherapy Surgery Prior splenectomy allow ( diagnosis , cytopenia , symptomatic splenomegaly )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>